AbbVie (NYSE:ABBV) Issues Q4 2025 Earnings Guidance

AbbVie (NYSE:ABBV) updated its fourth quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 3.320-3.360 for the period, compared to the consensus earnings per share estimate of 3.360. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.610-10.650 EPS.

Analysts Set New Price Targets

Several brokerages recently commented on ABBV. BMO Capital Markets lifted their price objective on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Evercore ISI upped their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Price Performance

Shares of ABBV stock opened at $233.65 on Thursday. AbbVie has a one year low of $164.39 and a one year high of $244.81. The company’s fifty day moving average price is $226.63 and its 200-day moving average price is $214.80. The company has a market capitalization of $412.95 billion, a price-to-earnings ratio of 177.01, a PEG ratio of 0.94 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 496.97%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg Bank raised AbbVie to a Buy, providing an analyst-driven demand tailwind that can support near-term share gains. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Multiple reports (WSJ/Reuters) said AbbVie was in advanced talks to acquire Revolution Medicines, fueling takeover speculation that typically lifts a buyer’s stock ahead of any deal announcement. AbbVie Near Deal for Revolution Medicines AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: AbbVie expanded its oncology pipeline with a first‑in‑human ABBV‑901 trial in ovarian cancer — a pipeline development that supports longer‑term growth narratives beyond legacy assets. AbbVie Expands Ovarian Cancer Pipeline With New ABBV‑901 Trial
• Neutral Sentiment: Revolution Medicines shares jumped on the takeover rumors (market context), which contributed to intraday volatility in AbbVie-related news flow but doesn’t change AbbVie’s fundamentals unless a deal is announced. Revolution Medicines stock surges over 20%
• Neutral Sentiment: AbbVie scheduled its full‑year and fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a routine event that will be the next formal opportunity for management to set expectations and move the stock. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: UBS reiterated a Hold rating, highlighting a balanced risk/reward given AbbVie’s premium valuation versus long-duration growth — a reminder that some analysts see limited upside from here. AbbVie: Premium Valuation… Hold Rating
• Negative Sentiment: AbbVie updated guidance: Q4 2025 EPS 3.320–3.360 and FY2025 EPS 10.610–10.650, each nudging slightly under consensus — a conservative tilt that can cap upside and explain some profit‑taking. (Company guidance released 1/8/2026)
• Negative Sentiment: After takeover reports, AbbVie publicly denied talks to buy Revolution Medicines, which may roll back some of the acquisition-driven rally and increase short-term volatility. Abbvie denies WSJ report of talks to buy Revolution Medicines
• Negative Sentiment: Competitive pressure: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads through December, underscoring intense competition in immunology that can pressure market share and pricing over time. Tremfya outstrips Skyrizi in TV ad spend

Hedge Funds Weigh In On AbbVie

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP purchased a new position in AbbVie during the third quarter valued at $41,000. Rakuten Securities Inc. grew its position in shares of AbbVie by 26.5% during the second quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock valued at $68,000 after purchasing an additional 77 shares in the last quarter. Binnacle Investments Inc increased its holdings in shares of AbbVie by 33.2% in the second quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock worth $92,000 after purchasing an additional 123 shares during the last quarter. Triumph Capital Management purchased a new stake in shares of AbbVie in the third quarter worth about $193,000. Finally, Turning Point Benefit Group Inc. purchased a new stake in shares of AbbVie in the third quarter worth about $213,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.